Introduction
Methods
Results
Value | |
---|---|
Age, years median (range) | 10 (2.9–15) |
Sex, no. (%) | |
Male | 10 (50) |
Female | 10 (50) |
Admission delay from first symptoms, days, median (range) | 6 (1–10) |
PELOD-2 score at admission, median (range) | 10 (10–22) |
Clinical description | |
Fever, no. (%) | 20 (100) |
Abdominal pain, no. (%) | 20 (100) |
Skin rash, no. (%) | 10 (50) |
Conjunctivitis, no. (%) | 6 (30) |
Cheilitis, no. (%) | 5 (25) |
Adenitis (diameter > 1.5 cm), no. (%) | 2 (10) |
Glasgow Coma Scale, median (range) | 15 (4–15) |
Hemodynamic features | |
Tachycardia, no. (%) | 20 (100) |
Systemic arterial hypotension, no. (%) | 20 (100) |
Left ventricular ejection fraction, median (range), % | 35 (25–55) |
Laboratory values, median (range)e | |
Troponin, ng/mL | 269 (31–4607) |
Brain natriuretic peptide, pmol/La | 3405 (179–19013) |
Lactate, mmol/L | 3.6 (1–8,1) |
Creatinine clearance, mL/min/1,73 m2 | 97 (16–170) |
Albumin, g/L | 21 (17–26) |
Sodium, mmol/L | 131 (122–139) |
Alanine aminotransferase, IU/L | 27 (6–163) |
Platelets count, per mm3 | 210, 000 (93,000–403,000) |
Neutrophil count, per mm3 | 10955 (1500–34200) |
Lymphocyte count, per mm3 | 1150 (380–7200) |
C-reactive protein, mg/L | 251 (94–458) |
Procalcitonin, ng/mLb | 46 (1,6–448) |
Fibrinogen, g/Lc | 7,2 (3,9–9) |
Inotropes and vasoactive drugs, no. (%) | 19 (95) |
Epinephrine, no. (%) | 12 (60) |
Median (range), µg/kg/min | 0.13 (0,1–0.5) |
Milrinone, no. (%) | 10 (50) |
Median (range), µg/kg/min | 0.45 (0.3–0.6) |
Dobutamine, no. (%) | 6 (30) |
Median (range), µg/kg/min | 7.5 (5–15) |
Norepinephrine, no. (%) | 4 (20) |
Median (range), µg/kg/min | 0.55 (0,2–1.2) |
Mechanical ventilation | |
Non-invasive ventilation, no. (%) | 11 (55) |
Invasive ventilation, no. (%) | 8 (40) |
High-flow nasal oxygen, no. (%) | 1 (5) |